Recent developments highlight Nexalin’s progress in clinical trials, regulatory interactions, leadership appointments, and capital raising activities supporting its neurostimulation technology advancement.

• Nexalin launched a pivotal clinical trial for the HALO Clarity device to support a planned FDA submission for insomnia treatment [N1].
• The company expanded peer-reviewed evidence supporting its DIFS non-invasive brain stimulation technology [N2].
• Nexalin received Nasdaq listing status notification in January 2026 [N3].
• Justin Van Fleet was appointed as CFO in August 2025 [N4].
• Nexalin hosted an investor webinar showcasing innovative neurostimulation advances in June 2025 [N5].
• The company closed a public offering of 3,850,000 shares at $1.30 per share, raising $5.0 million in May 2025 [N6].
• Nexalin priced the public offering at $1.30 per share, with the stock price declining in pre-market trading [N7].
• The company planned a Q-submission to the FDA for the Gen-2 SYNC system targeting cognitive disorders [N8].

Nexalin’s advanced neurostimulation technology addresses significant unmet needs in mental health and cognitive disorders, including anxiety, insomnia, depression, Alzheimer’s disease, and dementia. The proprietary 15 milliamp waveform and patented device designs offer potential clinical advantages with deeper brain stimulation and no adverse side effects. The company’s strategy to develop a virtual clinic platform for tele-psychiatry could improve patient access and adherence while reducing stigma associated with mental health treatment. Regulatory progress with FDA Q-submissions and approvals in China, Brazil, and Oman support potential market expansion. The company’s relationships with U.S. military and government agencies may open additional deployment channels. Recent capital raises provide funding for ongoing clinical trials and commercialization efforts.

Nexalin faces significant regulatory hurdles, with its Gen-2 and Gen-3 devices still undergoing FDA review and clinical trials, and no current FDA clearance for marketing in the U.S. The company has incurred substantial net losses and has limited revenue, reflecting early-stage commercialization. Market acceptance of neurostimulation devices remains uncertain, and reimbursement pathways are complex and evolving. The company’s stock is currently below Nasdaq’s minimum bid price requirement, posing listing risks. Manufacturing reliance on third-party contractors and potential supply chain disruptions could impact operations. Intellectual property challenges and competition from other mental health treatment modalities, including pharmaceuticals and psychotherapy, present ongoing risks. The company’s ability to transition from research and development to commercial success is unproven.

Nexalin’s moat is based on its proprietary 15 milliamp waveform technology, protected by multiple U.S. and foreign patents and pending applications. The advanced waveform enables deeper, non-invasive brain stimulation with no patient discomfort, differentiating its devices from competitors. The company’s integration of RFID technology for single-use electrodes supports recurring revenue and protects against generic knockoffs. Its development of a virtual clinic platform for tele-psychiatry and remote monitoring adds a service layer that may enhance patient adherence and physician oversight. Regulatory approvals in multiple countries and ongoing FDA interactions provide barriers to entry. However, the company remains in early commercial stages with ongoing clinical trials and regulatory reviews, which present execution risks.

• Regulatory Approval Risk: Gen-2 SYNC and Gen-3 HALO devices are undergoing FDA Q-submission and pre-submission processes but have not yet received marketing clearance, which is required for U.S. commercialization.
• Financial Risk: The company has incurred significant net losses and expects to continue incurring losses as it invests in clinical trials, regulatory approvals, and commercialization, requiring additional funding.
• Market Acceptance Risk: Adoption of neurostimulation devices for mental health treatment faces challenges including competition from established therapies, reimbursement complexities, and patient acceptance.
• Stock Listing Risk: Nexalin’s common stock is currently not in compliance with Nasdaq’s minimum bid price requirement, which could lead to delisting if compliance is not regained.
• Operational Risk: Dependence on third-party manufacturers and suppliers introduces risks related to supply chain disruptions and quality control.
• Intellectual Property Risk: The company’s competitive position depends on maintaining and enforcing its patents and proprietary technology against infringement and competition.

• Nexalin Technology, Inc. is headquartered in Houston, Texas, and develops neurostimulation medical devices targeting mental health conditions such as anxiety, insomnia, depression, Alzheimer's disease, and dementia [S1].
• The company’s original Generation 1 (Gen-1) device is a cranial electrotherapy stimulation (CES) device emitting 4 milliamps, classified as FDA Class II for anxiety and insomnia treatment but requiring new 510(k) clearance for marketing in the U.S. post-2019 FDA reclassification [S1].
• Gen-1 devices are no longer marketed for new sales in the U.S., but revenue is derived from prior sales and leasing through licensing fees and consumables like electrodes and cables [S1].
• Nexalin has developed Generation 2 (Gen-2 SYNC) and Generation 3 (Gen-3 HALO) devices emitting a proprietary 15 milliamp waveform designed for deeper brain stimulation with no patient discomfort or adverse side effects [S1].
• Gen-2 SYNC and Gen-3 HALO devices are undergoing FDA Q-submission and pre-submission processes, with clinical trials planned or ongoing in the U.S., Brazil, and China targeting mental health disorders including insomnia, anxiety, depression, Alzheimer's, and dementia [S1].
• The company is developing a virtual clinic platform to enable tele-psychiatry diagnosis and prescription of the Gen-3 HALO headset, with remote patient monitoring and monthly physician authorization to ensure safety and compliance [S1].
• Nexalin’s Gen-2 device has regulatory approval in China (NMPA), Brazil, and Oman, and the company has a joint venture in Hong Kong for clinical development and commercialization in China and the region [S1].
• Manufacturing is outsourced primarily to third-party contractors in the U.S. under FDA quality system regulations [S1].
• Nexalin holds multiple U.S. and foreign patents and pending applications protecting its proprietary waveform technology and device designs [S1].
• The company has a Military & Government Advisory Board to foster relationships with U.S. federal agencies including the Department of Defense and Veterans Affairs, aiming for device deployment in military and government settings [S1].
• Financial snapshot as of December 31, 2025: cash and equivalents of $654,783, short-term investments of $3,068,429, current assets of $4,299,270, current liabilities of $887,333, resulting in a current ratio of 4.85 and cash ratio of 4.2 [S1].
• For the fiscal year ended December 31, 2025, Nexalin reported revenue of $301,647 and a net loss of $8,222,181, with basic and diluted EPS of -$0.50 [S1].
• The company has incurred significant losses since inception and expects to continue incurring losses as it invests in clinical trials, regulatory approvals, and commercialization efforts [S1].
• Nexalin’s stock is listed on Nasdaq but is currently not in compliance with the minimum bid price requirement, with a compliance period extending to July 20, 2026 [S1].
• Recent news highlights include launching a pivotal clinical trial for the HALO Clarity device to support planned FDA submission for insomnia, expanding peer-reviewed evidence for its DIFS non-invasive brain stimulation technology, and receiving Nasdaq listing status notification [N1][N2][N3].
• The company appointed Justin Van Fleet as CFO in August 2025 and hosted an investor webinar showcasing neurostimulation advances in June 2025 [N4][N5].
• Nexalin closed a public offering in May 2025 raising $5.0 million through the sale of 3.85 million shares at $1.30 per share [N6][N7].
• The company plans Q-submission to FDA for the Gen-2 SYNC system targeting cognitive disorders [N8].